%PDF-1.4
%
96 0 obj
<>
endobj
93 0 obj
<>
endobj
159 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-03T10:24:27Z
2024-03-19T05:02:50-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-19T05:02:50-07:00
application/pdf
Heather
2001-302.feb
uuid:e6ca60f5-1dd1-11b2-0a00-6b08271d5700
uuid:e6ca60f7-1dd1-11b2-0a00-bf0000000000
endstream
endobj
82 0 obj
<>
endobj
83 0 obj
<>
endobj
97 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
28 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
41 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
49 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
52 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
65 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
197 0 obj
[201 0 R]
endobj
198 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.1465 Tw 7.76 0 0 8 54 714.5293 Tm
[(T)69.7 (oulouse; Prof. Meyer)39.7 (, Paris; Prof. Sany)64.9 (, Montpellier)39.7 (, France; Prof. Scott,)]TJ
-0.00861 Tw 0 -1.25 TD
[(London, UK; Prof. So, Lausanne, Switzerland; Prof. )17.8 (T)69.7 (ebib, L)54.8 (yon, France; Dr)54.8 (.)]TJ
0.061 Tw T*
[(Thompson, Poole, UK; Prof. )17.7 (T)34.8 (reves, Limoges, France; Prof. )17.7 (T)69.7 (yndall, Basle,)]TJ
0 Tc 0.076 Tw T*
[(Switzerland; Prof. )17.8 (V)111.1 (eys, Gent, Belgium; Prof. )17.8 (W)79.8 (endling, Besan\347on, France;)]TJ
-0.00011 Tc 0.00729 Tw T*
[(Dr)54.8 (. W)79.7 (esthovens, )-17.7 (Pellenbur)17.7 (g, )-17.8 (Belgium.)]TJ
0 Tc 0.0204 Tw T*
(Thanks also to David Chen and John Monyak, GlaxoSmithKline Biometrics,)Tj
0.00999 Tc 0.3649 Tw T*
[(for their tireless analysis of the two studies; Dr)54.6 (. Brian MacDonald,)]TJ
0 Tc -0.0009 Tw T*
[(GlaxoSmithKline, and Dr)54.9 (. John Lipani for their contributions to the program;)]TJ
0.02499 Tw T*
(and to IDEC Pharmaceuticals for their enthusiastic help and advice.)Tj
/TT1 1 Tf
-0.00011 Tc 0 Tw 9.7 0 0 10 54 610.5293 Tm
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.0249 Tw 7.76 0 0 8 61.18 600.5293 Tm
[(1.)-644.3 (Fox DA. )17.7 (The role of )17.7 (T)-257.2 (cells in the immunopathogenesis of rheumatoid)]TJ
1.3943 -1.25 Td
[(arthritis. )54.9 (Arthritis Rheum 1997;40:598-609.)]TJ
-1.3943 -1.25 Td
[(2.)-644.3 (Herzog C, )17.7 (W)79.8 (alker C, Muller )17.7 (W)91.8 (, et al. )54.8 (Anti-CD4 antibody treatment of)]TJ
1.3943 -1.25 Td
[(patients with rheumatoid arthritis: 1. Ef)17.8 (fect on clinical course and)]TJ
0.0072 Tw T*
[(circulating T)-257.2 (cells. )-17.7 (J )37.1 (Autoimmun )-17.8 (1989;2:627-42.)]TJ
-0.00011 Tc 0.02499 Tw -1.3943 -1.25 Td
[(3.)-644.4 (Hornef)17.7 (f G, Burmester GR, Emmrich F)79.7 (,)-0.1 ( Kalden JR. )17.7 (T)34.8 (reatment of)]TJ
0 Tc 1.3943 -1.25 Td
[(rheumatoid arthritis with an anti-CD4 monoclonal antibody)64.9 (. )54.9 (Arthritis)]TJ
T*
(Rheum 1991;34:129-40.)Tj
-1.3943 -1.25 Td
[(4.)-644.3 (Reiter C, Kakavand B, Rieber EP)110.8 (, Schattenkirchner M, Riethmuller G,)]TJ
1.3943 -1.25 Td
[(Kruger K. )17.7 (T)34.9 (reatment of rheumatoid arthritis with monoclonal CD4)]TJ
T*
[(antibody M-T151. Clinical results and immunopharmacologic ef)17.8 (fects)]TJ
T*
[(in an open study)64.9 (, including repeated administration. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1991;34:525-36.)Tj
0.0249 Tw -1.3943 -1.25 Td
[(5.)-644.3 (Goldber)17.8 (g D, Morel P)110.8 (, Chatenoud L, et al. Immunological ef)17.8 (fects of)]TJ
1.3943 -1.25 Td
(high dose administration of anti-CD4 antibody in rheumatoid arthritis)Tj
T*
[(patients. J )54.9 (Autoimmun 1991;4:617-30.)]TJ
-1.3943 -1.25 Td
[(6.)-644.3 (W)79.8 (endling D, Racadot E, Morel-Fourrier B, )17.7 (W)39.8 (ijdenes J. )17.7 (T)34.9 (reatment of)]TJ
1.3943 -1.25 Td
[(rheumatoid arthritis with anti CD4 monoclonal antibody)64.9 (. Open study)]TJ
T*
[(of 25 patients with the B-F5 clone. Clin Rheumatol 1992;1)36.8 (1:542-7.)]TJ
-1.3943 -1.25 Td
[(7.)-644.3 (Moreland L)74 (W)91.8 (, Bucy RP)110.8 (, )17.7 (T)34.9 (ilden )54.8 (A, et al. Use of a chimeric monoclonal)]TJ
1.3943 -1.25 Td
(anti-CD4 antibody in patients with refractory rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1993;36:307-18.)Tj
-1.3943 -1.25 Td
[(8.)-644.3 (van der Lubbe P)91.8 (A, Reiter C, Breedveld FC, et al. Chimeric CD4)]TJ
1.3943 -1.25 Td
(monoclonal antibody cM-T412 as a therapeutic approach to)Tj
T*
[(rheumatoid arthritis. )54.9 (Arthritis Rheum 1993;36:1375-9.)]TJ
-1.3943 -1.25 Td
[(9.)-644.3 (Choy EHS, Pitzalis C, Cauli )54.9 (A, et al. Percentage of anti-CD4)]TJ
1.3943 -1.25 Td
(monoclonal antibody-coated lymphocytes in the rheumatoid joint is)Tj
T*
(associated with clinical improvement. Implications for the)Tj
T*
[(development of immunotherapeutic dosing regimens. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1996;39:52-6.)Tj
-0.00011 Tc 0.02499 Tw -1.8943 -1.25 Td
[(10.)-644.4 (van der Lubbe P)91.7 (A, Dijkmans BAC, Markusse HM, Nassander U,)]TJ
0 Tc 1.8943 -1.25 Td
[(Breedveld FC. )54.9 (A)-219.8 (randomized, double-blind, placebo-controlled study)]TJ
T*
(of CD4 monoclonal antibody therapy in early rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1995;38:1097-106.)Tj
-1.8575 -1.25 Td
[(1)36.9 (1.)-644.3 (Moreland L)74 (W)91.8 (, Pratt PW)91.8 (, Mayes MD, et al. Double-blind, placebo-)]TJ
1.8575 -1.25 Td
(controlled multicentre trial using chimeric monoclonal anti-CD4)Tj
T*
[(antibody)64.9 (, cM-T412, in rheumatoid arthritis patients receiving)]TJ
T*
[(concomitant methotrexate. )54.9 (Arthritis Rheum 1995;38:1581-8.)]TJ
-1.8943 -1.25 Td
[(12.)-644.3 (W)79.8 (endling D, Racadot E, )17.8 (W)39.8 (ijdenes J, et al. )54.9 (A)-219.8 (randomized, double)]TJ
1.8943 -1.25 Td
(blind, placebo controlled multicenter trial of murine anti-CD4)Tj
T*
(monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol)Tj
0 Tw T*
(1998;25:1457-61.)Tj
0.02499 Tw -1.8943 -1.25 Td
[(13.)-644.3 (Epstein )17.8 (WV)128.9 (. Expectation bias in rheumatoid arthritis clinical trials.)]TJ
1.8943 -1.25 Td
[(The anti-CD4 monoclonal antibody experience. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1996;39:1773-80.)Tj
0.0249 Tw -1.8943 -1.25 Td
[(14.)-644.3 (T)69.8 (ak PP)110.8 (, van der Lubbe P)91.8 (A, Cauli )54.8 (A, et al. Reduction of synovial)]TJ
1.8943 -1.25 Td
(inflammation after anti-CD4 monoclonal antibody treatment in early)Tj
T*
[(rheumatoid arthritis. )54.9 (Arthritis Rheum 1995;38:1457-65.)]TJ
-1.8943 -1.25 Td
[(15.)-644.3 (Moreland L)74 (W)91.8 (, Haverty )17.7 (TP)110.9 (, )17.7 (W)79.8 (acholtz MC, et al. Nondepleting)]TJ
1.8943 -1.25 Td
(humanized anti-CD4 monoclonal antibody in patients with refractory)Tj
T*
(rheumatoid arthritis. J Rheumatol 1998;25:221-8.)Tj
32.1263 76.75 Td
[(16.)-644.3 (Chu C-Q, Londei M. Induction of )17.8 (Th2 cytokines and control of)]TJ
1.8943 -1.25 Td
[(collagen-induced arthritis by nondepleting anti-CD4 )54.8 (Abs. J Immunol)]TJ
0 Tw T*
(1996;157:2685-9.)Tj
0.0249 Tw -1.8943 -1.25 Td
[(17.)-644.3 (Newman R, )54.8 (Alberts J, )54.8 (Anderson D, et al. \223Primatization\224 of)]TJ
1.8943 -1.25 Td
(recombinant antibodies for immunotherapy of human diseases: a)Tj
T*
(macaque/human chimeric antibody against human CD4.)Tj
T*
(Biotechnology 1992;10:1455-60.)Tj
-0.00011 Tc -1.8943 -1.25 Td
[(18.)-644.4 (Anderson D, Chambers K, Hanna N, et al. )54.8 (A)-219.9 (primatized Mab to)]TJ
0 Tc 1.8943 -1.25 Td
(human CD4 causes receptor modulation, without marked reduction in)Tj
T*
[(CD4+ )17.8 (T)-257.2 (cells in chimpanzees: in vitro and in vivo characterization of)]TJ
T*
(a Mab \(IDEC-CE9.1\) to human CD4. Clin Immunol Immunopathol)Tj
0 Tw T*
(1997;84:73-84.)Tj
0.0249 Tw -1.8943 -1.25 Td
[(19.)-644.3 (Podolin PL, )17.7 (W)79.8 (ebb EF)79.8 (, Reddy M, )17.7 (T)34.9 (r)0.1 (uneh )54.8 (A, Griswold DE. Inhibition)]TJ
1.8943 -1.25 Td
(of contact sensitivity in human CD4+ transgenic mice by human CD4-)Tj
T*
[(specific monoclonal antibodies: CD4+ )17.8 (T)91.8 (-cell depletion is not required.)]TJ
T*
(Immunology 2000;99:287-95.)Tj
-1.8943 -1.25 Td
[(20.)-644.3 (Y)100.1 (ocum DE, Solinger )54.9 (AM, )17.8 (T)69.8 (esser J, et al. Clinical and immunologic)]TJ
-0.00011 Tc 1.8943 -1.25 Td
[(ef)17.7 (fects of a Primatized)]TJ
0 Tc 0 Tw 5.04 0 0 5.2 406.4543 547.1693 Tm
(\256)Tj
0.02499 Tw 7.76 0 0 8 412.4205 544.5293 Tm
(anti-CD4 monoclonal antibody in active)Tj
-9.848 -1.25 Td
(rheumatoid arthritis: results of a phase I, single dose, dose escalating\
)Tj
T*
(trial. J Rheumatol 1998;25:1257-62.)Tj
-1.8943 -1.25 Td
[(21.)-644.3 (Kaine J, Solinger )54.8 (A, )36.8 (Y)100.1 (ocum D, et al. Results of a multi-dose protocol)]TJ
1.8943 -1.25 Td
[(7002 using an immunomodulating, non-depleting Primatized\231)-275 (anti-)]TJ
T*
[(CD4 monoclonal antibody in rheumatoid arthritis [abstract]. )54.9 (Arthritis)]TJ
T*
(Rheum 1995;38 Suppl:S185.)Tj
-0.00011 Tc -1.8943 -1.25 Td
[(22.)-644.4 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.8943 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification of)]TJ
0 Tc T*
[(rheumatoid arthritis. )54.9 (Arthritis Rheum 1988;31:315-24.)]TJ
-0.00011 Tc -1.8943 -1.25 Td
[(23.)-644.4 (Felson DT)73.9 (, )54.8 (Anderson JJ, Boers M, et al. )54.8 (American College of)]TJ
0 Tc 1.8943 -1.25 Td
(Rheumatology preliminary definition of improvement in rheumatoid)Tj
T*
[(arthritis. )54.9 (Arthritis Rheum 1995;38:727-35.)]TJ
-1.8943 -1.25 Td
[(24.)-644.3 (Smolen J, Breedveld F)79.8 (, Eberl G, et al. )17.7 (V)111.1 (ariability and reliability of the)]TJ
1.8943 -1.25 Td
(twenty-eight joint count for the assessment of rheumatoid arthritis)Tj
T*
[(activity)64.9 (. )54.9 (Arthritis Rheum 1995;38:38-43.)]TJ
-0.00011 Tc -1.8943 -1.25 Td
[(25.)-644.4 (Pincus )17.7 (T)73.9 (, Summey JA, Soraci SA)-220.2 (Jr)39.7 (, )17.7 (W)79.7 (allaston KA, Hummon NP)110.7 (.)]TJ
0 Tc 1.8943 -1.25 Td
(Assessment of patient satisfaction in activities of daily living using a\
)Tj
-0.00011 Tc T*
[(modified Stanford Health )54.8 (Assessment Questionnaire. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1983;26:1346-53.)Tj
0.0249 Tw -1.8943 -1.25 Td
[(26.)-644.3 (Reddy MP)110.8 (, Kinney CAS, Chaikin MA, et al. Elimination of Fc)]TJ
1.8943 -1.25 Td
[(receptor)19.8 (-dependent ef)17.8 (fector functions of a modified IgG4 monoclonal)]TJ
T*
(antibody to human CD4. J Immunol 2000;164:1925-33.)Tj
-1.8943 -1.25 Td
[(27.)-644.3 (Bugelski PJ, Herzyk DJ, Rehm S, et al. Preclinical development of)]TJ
1.8943 -1.25 Td
[(keliximab, a Primatized\231)-275 (anti-CD4 monoclonal antibody)64.9 (, in human)]TJ
T*
(CD4 transgenic mice: characterization of the model and safety studies.)Tj
T*
[(Hum Exp )17.8 (T)69.8 (oxicol 2000;19:230-43.)]TJ
-1.8943 -1.25 Td
[(28.)-644.3 (Sharma )54.8 (A, Davis C, )17.7 (T)69.8 (obia L, et al. Comparative pharmacodynamics of)]TJ
1.8943 -1.25 Td
(keliximab and clenoliximab in transgenic mice bearing human CD4. )Tj
T*
[(J Pharmacol Exp )17.7 (Ther 2000;293:33-4.)]TJ
-0.00011 Tc -1.8943 -1.25 Td
[(29.)-644.4 (Hochber)17.7 (g )36.8 (Y)129.1 (.)-0.1 ( )54.8 (A)-219.9 (sharper Bonferroni procedure for multiple test of)]TJ
0 Tc 1.8943 -1.25 Td
(significance. Biometrika 1988;75:800-2.)Tj
-1.8943 -1.25 Td
[(30.)-644.3 (Y)100.1 (ang H, Parkhouse RME. Dif)17.8 (ferential activation requirements)]TJ
1.8943 -1.25 Td
[(associated with stimulation of )17.7 (T)-257.2 (cells via dif)17.8 (ferent epitopes of CD3.)]TJ
T*
(Immunology 1998;93:26-32.)Tj
-1.8943 -1.25 Td
[(31.)-644.3 (Levy R, )17.7 (W)79.8 (eisman M, )17.7 (W)39.8 (iesenhutter C, et al. Results of a placebo-)]TJ
1.8943 -1.25 Td
[(controlled multicenter trial using a Primatized\231)-275 (non-depleting anti-)]TJ
T*
(CD4 monoclonal antibody in the treatment of rheumatoid arthritis)Tj
T*
[([abstract]. )54.9 (Arthritis Rheum 1996;39 Suppl:S123.)]TJ
-0.00011 Tc -1.8943 -1.25 Td
[(32.)-644.4 (Roitt I, Brostof)17.7 (f J, Male D. Immunology)64.8 (. 3rd ed. London: Mosby-Y)99.7 (ear)]TJ
0 Tc 1.8943 -1.25 Td
(Book Europe Ltd.; 1993.)Tj
-0.00011 Tc -1.8943 -1.25 Td
[(33.)-644.4 (W)39.7 (ing MG, Moreau )17.7 (T)73.9 (, Greenwood J, et al. Mechanism of first-dose)]TJ
0 Tc 1.8943 -1.25 Td
(cytokine-release syndrome by Campath 1-H: Involvement of CD16)Tj
-0.0002 Tc 0 Tw T*
(\(Fc)Tj
/T1_0 1 Tf
0 Tc [-0.1 (\003)]TJ
/TT0 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (RIII\) and CD1)36.7 (1a/CD18 \(LF)73.9 (A-1\) on NK cells. J Clin Invest)]TJ
0 Tc 0 Tw T*
(1996;98:2819-26.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT2 1 Tf
0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Mason, et al: Efficacy pr)36.9 (edictors in RA)]TJ
0 Tw 61.4375 -0.0313 Td
(229)Tj
ET
0 0 0 0 scn
/GS0 gs
101.25 59.75 407.5 -10.83 re
f*
0.5 w
101.25 59.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_1 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_2 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 19, 2024 from )Tj
ET
endstream
endobj
69 0 obj
<>
endobj
138 0 obj
<>
endobj
164 0 obj
<>
endobj
111 0 obj
<>
endobj
116 0 obj
<>
endobj
99 0 obj
<>
endobj
101 0 obj
<>
endobj
133 0 obj
<>stream
HV pTU= ${>
K!i tRR",`1|FR(D`@(YX Nشj{;_7VFӿtDIeJLJ觶ϋ@]^5!"P)+_emW63G
i> ߩrI˜ Wg0?S<20*@M>[iOTx@e1{uTzm}լ~x(ue."U*Xg8+phzj\,
ԣ320Yڊ(%FHlF"
1M\PcKkOy)>+3/cvNwFdu]'bx+p=wFL`$'|ed\sKQi[,FbK>]Ncb,j1C#XdgD9G
=֗v>,[,k1pW1V'k`Tt~J0+鷞3lpED>bb8(NIR(Xu)̳&{y$
|:r"Qt9@l9Y.g;UQka&p0=ȼ?1o!HF{n
m^aeΣwq_h!"EgM/✌Ґy%SPO4Oheg[3O9eGneL$R^j/d춈m)|_pc8:nC#nYDX8&\ZV+FjPԈEM(vOafP@.F^7OJ8Cj:NݮhZ#[^BCաÊ2jkѪgUg2 dUa'm&e62:}³tѝ`
# !2I<#*dDcDb$E)^2-FI;~qMY^MF6RYL,bTr|[#gi)-%MQ)#2SYlV(۔+ǕF@yyHuZݧa^kekZVMӦkANۥE0c
RZG6soړ><*="w^uIka(;ϻNjCJ$*k^úH.:ti5oQ\URݭk]Yu~6=ޱCjJĄvmi:UtQMU@tC o
~a3iK7-fnt?z_ueC7z7X7ᱚ
ݓXQ¯{A}{+
mյ=,Hdg[xdc&a Q>OA{ؕec c:yyس7#Z Y{c1ٟ]jL%Plo&L0
̄/%>>y7+/Siʴ`fِߞs6E>b)ӱnӵ7QfxlnFT?s41zsWr⏚GNs@{8P%ɭ'=qe5$.d\]3qaSEM{[\`?t 0|Cɵr,ɥb$bFji,xiIY#]Gc33`Y2=\Yf{*V73U2̻ilY91kF:&wvf)fCM\yyo4W,ΌLiSG]hdEZ+_)B̛Q2^V9&c!+"iItK/yM۞(!$R~zb 5|~(?s植Evj[K;4VºI}=ꫛ[Pgc(q|erg6~}G}ػe^Kc4 %Pq۱{]C8ym3I#JuGnq4}ȎێaLaM~I4c?G"Q)b*OX+ҕd_[/KadcK`c#lZFd&1!Ĵƀ!N$0$j\W%0vNH:53f4iK-J:L9ٳ{L[FaVUC{AClGtVauo$^N .|kA}6
wrdX{`}ķjs1a+nqCu ,&M㥱kyEBP!>m]۩'y>d$Qy=D2r; Q| ꟁyy,w9
9OloW%Y6TtV ? b}˝Gr9S@ɻ\w@E"26G ~#0wJӾRh} 0
Jz U
= J^HUk )*y. J^Ыd7] :thU@P J@0 X% Jt@12`vh56R_B[sCpmĵpfyTcĿrkHjD.\%ɵV5H
` U6Hpa8ndGHz~>I!iUH*
I!Iŷdst[e-tKzLz}:2_=8,I,?F>/$q^Q-<8@=k!.*^
W(^,^
!Caޥ)5f܈\3!Pa(]GkWAV
#/pFҍ9aKg(xi?QzIp~Q 9JR4GEt'p' a8`.az3Jw!.p;J_coJ:/Z8]I_Y.nc/:/ B4/XOn$j)V3y8^ atmuA9_wsEQATRQY(*R(*٢%IOzN/ Z·cLt/
j^= t4=BzISIv$wdt$K`fcFC8=텣 ?mv[v{T._I]
S|aW"g/
'(J@e48J\F!6Ng6_p)y)m'(}I㔾$ex<@0PClnܔ0&̅\M:0k߇|qI~g:ɉ9`غm@d V$ʗ
2 FSD
-ވ`πnDJ$TAfU7G}V㚪
Sc}dv9QHFb1XaǴ6S"gHޟ:kd8̮ba;